FinnDiane LifeOne Study - Impact of Ageing on People With Type 1 Diabetes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Diabetes Mellitus Type 1, Healthy Ageing. Basic parameters: from 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Healthy aging refers to functional ability that enables well-being in older individuals. The focus thus shifts from chronological age to functional capacity and the individual's own experience of well-being. Type 1 diabetes is a chronic condition characterized by elevated blood glucose levels, which increases the risk of cardiovascular diseases and premature death. However, the life expectancy of individuals with type 1 diabetes has significantly improved due to advances in diabetes care. There is limited research on aging with type 1 diabetes, and this study is at the forefront of addressing this gap by examining aging-and especially healthy aging-in type 1 diabetes from multiple perspectives. The goals are to investigate how individuals with type 1 diabetes age and what their functional capacity is compared to individuals without insulin-treated diabetes. The other aim is to identify factors in midlife that predict healthy aging in people with type 1 diabetes.
Detailed description
Ageing with type 1 diabetes is an emerging challenge due to improved life-expectancy of people with type 1 diabetes. While those who survive to an older age are considered survivors, the many years with type 1 diabetes and the chronic dysglycaemia inevitably also has negative health impacts on people living with this chronic disease. With scarce research in this area, ageing in type 1 diabetes has been identified as a research gap.
With this study, the aim is to assess the impact of ageing in people with type 1 diabetes via thorough characterization of older adults with type 1 diabetes, in comparison to matched controls. This will be accomplished through a comprehensive assessment of the participants' metabolic profile, body composition, vascular health, autonomic function, and a geriatric assessment focusing on the functional ability of the participants. In addition, this study will assess what type of challenges older adults with type 1 diabetes face regarding self-management, diabetes care, and daily life.
This study is a sub-study of the national Finnish Diabetic Nephropathy Study, initiated in 1997 and including adults with type 1 diabetes. Individuals over 65 living in the Helsinki capital area will now be invited for a regular FinnDiane study visit, as well as an additional visit for a geriatric assessment. The aim is to study 300 FinnDiane study participants and recruit a minimum of 100 matched controls. This cohort will be prospectively followed with a revisit after three to five years.
Primary outcome measures
- Healthy ageing in people with type 1 diabetes mellitus [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
Secondary outcome measures (5)
- Physical capacity [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Cognitive function [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Psychological well-being [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Vitality [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Sensory function [Time frame: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
Eligibility criteria
Inclusion criteria
- Participants of the Finnish Diabetic Nephropathy Study
- Type 1 diabetes
- With age above 65 years
- Informed consent provided
Exclusion criteria
- Age below 65 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Finland · 1 center
- HUS Helsinki University Hospital — Helsinki
Identifiers
NCT: NCT07289204 · HUS/4387/2023